CX717 information

CX717
Clinical data
Routes of; administration	By mouth, IV
ATC code	None;
Identifiers
	IUPAC name 5-(Morpholine-4-carbonyl)-2,1,3-benzoxadiazole;
CAS Number	867276-98-0 ;
PubChem CID	3323368;
ChemSpider	2570822;
UNII	7I12YTA3QM;
Chemical and physical data
Formula	C11H11N3O3
Molar mass	233.227 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1COCCN1C(=O)C2=CC3=NON=C3C=C2;
	InChI InChI=1S/C11H11N3O3/c15-11(14-3-5-16-6-4-14)8-1-2-9-10(7-8)13-17-12-9/h1-2,7H,3-6H2; Key:KFRQROSRKSVROW-UHFFFAOYSA-N;
	(what is this?)

CX717 is an ampakine compound created by Christopher Marrs and Gary Rogers in 1996^[3] at Cortex Pharmaceuticals. It affects the neurotransmitter glutamate, with trials showing the drug improves cognitive functioning and memory.^[4]

^ Radin DP, Purcell R, Lippa AS (January 2018). "Oncolytic Properties of Ampakines In Vitro". Anticancer Research. 38 (1): 265–269. doi:10.21873/anticanres.12217. PMID 29277782.
^ Purcell R, Lynch G, Gall C, Johnson S, Sheng Z, Stephen MR, et al. (April 2018). "Brain Vacuolation Resulting From Administration of the Type II Ampakine CX717 Is An Artifact Related to Molecular Structure and Chemical Reaction With Tissue Fixative Agents". Toxicological Sciences. 162 (2): 383–395. doi:10.1093/toxsci/kfx277. PMID 29253237.
^ US 6110935, Rogers GA, Marrs CM, "Benzofurazan compounds for enhancing glutamatergic synaptic responses", issued 29 August 2000, assigned to University of California.
^ Hampson RE, España RA, Rogers GA, Porrino LJ, Deadwyler SA (January 2009). "Mechanisms underlying cognitive enhancement and reversal of cognitive deficits in nonhuman primates by the ampakine CX717". Psychopharmacology. 202 (1–3): 355–369. doi:10.1007/s00213-008-1360-z. PMC 3107999. PMID 18985324.

[1] Radin DP, Purcell R, Lippa AS (January 2018). "Oncolytic Properties of Ampakines In Vitro". Anticancer Research. 38 (1): 265–269. doi:10.21873/anticanres.12217. PMID 29277782.

[2] Purcell R, Lynch G, Gall C, Johnson S, Sheng Z, Stephen MR, et al. (April 2018). "Brain Vacuolation Resulting From Administration of the Type II Ampakine CX717 Is An Artifact Related to Molecular Structure and Chemical Reaction With Tissue Fixative Agents". Toxicological Sciences. 162 (2): 383–395. doi:10.1093/toxsci/kfx277. PMID 29253237.

[3] US 6110935, Rogers GA, Marrs CM, "Benzofurazan compounds for enhancing glutamatergic synaptic responses", issued 29 August 2000, assigned to University of California.

[pmid18985324-4] Hampson RE, España RA, Rogers GA, Porrino LJ, Deadwyler SA (January 2009). "Mechanisms underlying cognitive enhancement and reversal of cognitive deficits in nonhuman primates by the ampakine CX717". Psychopharmacology. 202 (1–3): 355–369. doi:10.1007/s00213-008-1360-z. PMC 3107999. PMID 18985324.

CX717 information

and 7 Related for: CX717 information

CX717

Ampakine

RespireRx

Psychoactive drug

Analeptic

Opioid

Neurolaw

Clinical data

Routes of administration	By mouth, IV
ATC code	None
Identifiers
IUPAC name 5-(Morpholine-4-carbonyl)-2,1,3-benzoxadiazole^[1]^[2]
CAS Number	867276-98-0^Y
PubChem CID	3323368
ChemSpider	2570822
UNII	7I12YTA3QM
Chemical and physical data
Formula	C₁₁H₁₁N₃O₃
Molar mass	233.227 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C1COCCN1C(=O)C2=CC3=NON=C3C=C2
InChI InChI=1S/C11H11N3O3/c15-11(14-3-5-16-6-4-14)8-1-2-9-10(7-8)13-17-12-9/h1-2,7H,3-6H2 Key:KFRQROSRKSVROW-UHFFFAOYSA-N
^NY (what is this?)